ClinicalTrials.gg
SuspendedNCT05961007Updated Jul 27, 2023

Evaluation of IBI302 Injection in nAMD or DME

A Phase 1/2 interventional study of Intravitreal injection of IBI302(dose 1) and Intravitreal injection of IBI302(dose 2) in Neovascular Age-related Macular Degeneration and Diabetic Macular Edema, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Suspended at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-27.

Primary conditionMacular EdemaRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Macular Edema
Why
  1. The study's listed conditions name Macular Edema, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1/2, Interventional, and Treatment

Why this study was suspended
Company strategy adjustment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.

Planned enrollment
27th of 65
234 · median 140
Started
2021
with 4 others
Phase 1/2
7 of 72
2 open now
Registered
34th of 72
by date

Among the 72 studies in Macular Edema with a site in China, this one is the 27th largest by planned enrollment of the 65 interventional ones that give a count, is one of 5 that started in 2021, is one of 7 in phase 1/2, and was the 34th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Macular Edema with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema

Browse trials for

04

In context

Macular Edema Reclassified

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

This study's planned enrollment of 234 is above the median of 56 across 586 interventional studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to sign form and comply with visit and study procedures per protocol;
  2. Male or female patiensubjects ≥ 18 yrs. of age;
  3. For AMD subjects, active subfoveal or parafoveal CNV secondary to neovascular AMD; the vision decreased by nAMD;
  4. For DME subjects, Type 1 or type 2 diabetes mellitus, decrease in vision determined to be primarily the result of DME in the study eye; the CST measurement of ≥ 280 μm in the study eye;
  5. BCVA ETDRS letter score of 24-73 in the study eye;

Exclusion criteria

Exclusion criteria

  1. Concomitant diseases that may cause subjects fail to respond to the treatment or confuse the interpretation of the study results;
  2. Presence of uncontrolled glaucoma in the study eye ;
  3. Presence of active intraocular or periocular inflammation or infection;
  4. Prior any treatment of following in the study eye:

    1. Anti-VEGF therapy or anti-complement therapy;
    2. Laser photocoagulation;
    3. History of vitreoretinal surgery;
    4. treatment(intravitreal or peribulbar) ;
  5. BCVA score \<19 letters in the fellow eye;
  6. Anti-VEGF therapy in the fellow eye within 30 days of day 0;
  7. Presence of any systemic disease: including but not limited to active infections (such as active viral hepatitis); unstable angina; cerebrovascular accident or transient cerebral ischemia (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening; serious arrhythmia requiring medical treatment; liver, kidney or metabolic diseases; uncontrolled clinical disease(such as diabetes mellitus, hypertension) or malignant tumor;
  8. History of severe /allergy to active ingredients or any of the study drug, or fluorescein and povidone iodine;
  9. Pregnant or lactating women or women preparing to become pregnant or breastfeeding during the study period;
  10. Participated in any clinical study of any other drug within 90 days of day 0, or attempted to participate in other drug trials during the study;
  11. Other conditions unsuitable for enrollment judged by investigatiors.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
234 participants (estimated)

Study arms

  • Active comparator
    Aflibercept

    only phase II

    Drug: Intravitreal injection of Aflibercept

  • Experimental
    IBI302

    Biological: Intravitreal injection of IBI302(dose 1) · Biological: Intravitreal injection of IBI302(dose 2) · Biological: Intravitreal injection of IBI302(dose 3)

Interventions

  • BiologicalIntravitreal injection of IBI302(dose 1)

    IBI302(dose 1) intravitreal injection given as protocol

  • BiologicalIntravitreal injection of IBI302(dose 2)

    IBI302(dose 2) intravitreal injection given as protocol

  • BiologicalIntravitreal injection of IBI302(dose 3)

    IBI302(dose 3) intravitreal injection given as protocol

  • DrugIntravitreal injection of Aflibercept

    Aflibercept intravitreal injection given as protocol

07

What researchers measure

Primary outcomes

  1. Incidence and severity of ocular and non-ocular adverse events.

    To evaluate the number of subjects with ocular and non-ocular adverse events, treatment emergent adverse event, adverse event of special interest, serious adverse events; number of subjects with clinical significant abnormal laboratory values, electrocardiograms (pre and post infusions), abnormal vital signs, ophthalmic and physical examinations.

    Time frame: Up to week 20

  2. DLT in each group

    Time frame: 7 days

Secondary outcomes

  1. Change of BCVA from baseline by visit

    Best corrected visual acuity (BCVA) was measured on early treatment diabetic retinopathy study(ETDRS) chart at a starting distance of 4 meters. The BCVAletter score ranges from 0 to 100(best score), and a gain in BCVA from baseline indicates an improvement in visual acuity.

    Time frame: through study completion,an average of 20 weeks

  2. Change of CST from baseline by visit

    Central subfield thickness(CST) was defined as the distance between the internal limiting member and the Bruch's member using OCT, as assessed by the central reading.

    Time frame: through study completion,an average of 20 weeks

  3. Area under the concentration time curve (AUC) and Maximum plasma concentration (Cmax)

    Time frame: through study completion,an average of 20 weeks

  4. The ADA and neutralizing antibody

    Blood samples were obtained for measurement of anti-drug antibodies (ADAs) to IBI302 by a validated enzyme-linked immunosorbent assay (ELISA).

    Time frame: through study completion,an average of 20 weeks

08

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Oct 2023, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Jul 27, 2023
StartActual
Nov 18, 2021
Primary completionEst.
Oct 31, 2023
CompletionEst.
Apr 30, 2024
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05961007
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Nov 18, 2021
Primary completion
Oct 31, 2023 (estimated)
Completion
Apr 30, 2024 (estimated)
Last update
Jul 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion